Evaxion's AI-Immunology Platform Shows 86% Vaccine Target Recognition in Cancer, Completes EVX-01 Phase 2 Extension
EVAX has more than doubled off its 52-week low of $1.42 on light trading volume (0.3× avg).
Summary
Evaxion announced a positive business update, highlighting significant progress in its AI-Immunology™ platform and pipeline. Key developments include new data demonstrating an 86% vaccine target recognition for its personalized cancer vaccine EVX-01, providing strong scientific validation for the platform's precision. The company also successfully completed the one-year extension of its EVX-01 Phase 2 trial, with three-year clinical data expected in the second half of 2026. Further positive data confirmed the platform's scalability for glioblastoma and new polio vaccine design concepts from its Gates Foundation collaboration. While the promotion of Birgitte Rønø to Chief Scientific and Operating Officer was previously announced in a 6-K filing on April 27, these R&D milestones are new and highly material for a clinical-stage biotech. The company also confirmed an unchanged cash runway into the second half of 2027, providing financial stability. These advancements underscore the therapeutic potential of Evaxion's platform and could significantly impact its valuation.
At the time of this announcement, EVAX was trading at $4.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.8M. The 52-week trading range was $1.42 to $12.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.